Basal-Only Insulin Delivery System Cleared for Patients With Type 2 Diabetes

The Food and Drug Administration (FDA) has cleared the Omnipod GO^™ insulin delivery device for individuals 18 years of age and older with type 2 diabetes.

Omnipod GO is a standalone, wearable, tubeless insulin delivery system designed to provide a fixed rate of continuous rapid-acting insulin for 72 hours. The following U-100 insulins are cleared for use with the Pod: NovoLog^®, Fiasp^®, Humalog^®, Admelog^®, and Lyumjev^®. The Pod will be offered in 7 different pre-programmed daily rates, ranging from 10 to 40 units per day.

“Omnipod GO was designed to serve the more than 3 million people using basal insulin or transitioning to insulin therapy to treat their type 2 diabetes,” said Jim Hollingshead, President and CEO. “Our goal is to help people with type 2 diabetes successfully shift to insulin therapy with a product that fundamentally changes how they feel about diabetes management. We’re excited to bring this new solution to market and deliver on our mission to simplify life for people with diabetes.”

The Omnipod GO is expected to be available in the US in 2024. The Omnipod product line currently includes the Omnipod 5 and the Omnipod DASH insulin delivery systems.